DND Pharmatech (KOSDAQ:347850) secured a contract to provide research services for the formulation development of an anti-obesity drug from New York-based biomedical firm Pfizer, according to a Thursday filing with the Korea Exchange.
The deal, valued at 1.83 billion won, is valid till Nov. 30.
Shares of DND Pharmatech rose nearly 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments